British health care: It's come to this

A drug that can prolong the lives of patients with advanced liver cancer has been rejected for use in the NHS in England, Wales and Northern Ireland.

The National Institute for Health and Clinical Excellence (NICE) said the cost of Nexavar – about £3,000 a month – was “simply too high”.

Advertisement

But Macmillan Cancer Support said the decision was “a scandal”.

Join the conversation as a VIP Member

Trending on HotAir Videos

Advertisement
Advertisement
Advertisement